Cargando…
Clinical Implications of Helicobacter pylori Antibiotic Resistance in Italy: A Review of the Literature
Helicobacter pylori (H. pylori) resistance to antibiotics has increased worldwide in recent decades, especially to clarithromycin. As a result, the World Health Organization (WHO) identified clarithromycin-resistant H. pylori as a “high priority” pathogen in 2017. As international guidelines recomme...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598780/ https://www.ncbi.nlm.nih.gov/pubmed/36290110 http://dx.doi.org/10.3390/antibiotics11101452 |
_version_ | 1784816436217118720 |
---|---|
author | Nista, Enrico Celestino Pellegrino, Antonio Giuli, Lucia Candelli, Marcello Schepis, Tommaso De Lucia, Sara Sofia Ojetti, Veronica Franceschi, Francesco Gasbarrini, Antonio |
author_facet | Nista, Enrico Celestino Pellegrino, Antonio Giuli, Lucia Candelli, Marcello Schepis, Tommaso De Lucia, Sara Sofia Ojetti, Veronica Franceschi, Francesco Gasbarrini, Antonio |
author_sort | Nista, Enrico Celestino |
collection | PubMed |
description | Helicobacter pylori (H. pylori) resistance to antibiotics has increased worldwide in recent decades, especially to clarithromycin. As a result, the World Health Organization (WHO) identified clarithromycin-resistant H. pylori as a “high priority” pathogen in 2017. As international guidelines recommend empirical therapy as first-line treatment, it is crucial to know local resistance rates and history of antibiotic use to determine the most appropriate first-line antibiotic treatment. Italy is one of the European countries with the highest prevalence of H. pylori infection and the highest percentage of antibiotic-resistant H. pylori. The aim of this review is to summarize all data on H. pylori antibiotic resistance in Italy in order to quantify the current rate and determine the most effective therapeutic approach. The study confirms an elevated level of resistance to clarithromycin, metronidazole, and levofloxacin in Italy. In addition, our results show a satisfactory eradication rate for a bismuth-based regimen when used as first- or second-line treatment. Naive patients are also successfully treated with clarithromycin-based quadruple therapies. Considering the good results of bismuth-based therapy as recovery therapy, this argues for the potential use of clarithromycin quadruple therapy as a first-line treatment. |
format | Online Article Text |
id | pubmed-9598780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95987802022-10-27 Clinical Implications of Helicobacter pylori Antibiotic Resistance in Italy: A Review of the Literature Nista, Enrico Celestino Pellegrino, Antonio Giuli, Lucia Candelli, Marcello Schepis, Tommaso De Lucia, Sara Sofia Ojetti, Veronica Franceschi, Francesco Gasbarrini, Antonio Antibiotics (Basel) Review Helicobacter pylori (H. pylori) resistance to antibiotics has increased worldwide in recent decades, especially to clarithromycin. As a result, the World Health Organization (WHO) identified clarithromycin-resistant H. pylori as a “high priority” pathogen in 2017. As international guidelines recommend empirical therapy as first-line treatment, it is crucial to know local resistance rates and history of antibiotic use to determine the most appropriate first-line antibiotic treatment. Italy is one of the European countries with the highest prevalence of H. pylori infection and the highest percentage of antibiotic-resistant H. pylori. The aim of this review is to summarize all data on H. pylori antibiotic resistance in Italy in order to quantify the current rate and determine the most effective therapeutic approach. The study confirms an elevated level of resistance to clarithromycin, metronidazole, and levofloxacin in Italy. In addition, our results show a satisfactory eradication rate for a bismuth-based regimen when used as first- or second-line treatment. Naive patients are also successfully treated with clarithromycin-based quadruple therapies. Considering the good results of bismuth-based therapy as recovery therapy, this argues for the potential use of clarithromycin quadruple therapy as a first-line treatment. MDPI 2022-10-21 /pmc/articles/PMC9598780/ /pubmed/36290110 http://dx.doi.org/10.3390/antibiotics11101452 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Nista, Enrico Celestino Pellegrino, Antonio Giuli, Lucia Candelli, Marcello Schepis, Tommaso De Lucia, Sara Sofia Ojetti, Veronica Franceschi, Francesco Gasbarrini, Antonio Clinical Implications of Helicobacter pylori Antibiotic Resistance in Italy: A Review of the Literature |
title | Clinical Implications of Helicobacter pylori Antibiotic Resistance in Italy: A Review of the Literature |
title_full | Clinical Implications of Helicobacter pylori Antibiotic Resistance in Italy: A Review of the Literature |
title_fullStr | Clinical Implications of Helicobacter pylori Antibiotic Resistance in Italy: A Review of the Literature |
title_full_unstemmed | Clinical Implications of Helicobacter pylori Antibiotic Resistance in Italy: A Review of the Literature |
title_short | Clinical Implications of Helicobacter pylori Antibiotic Resistance in Italy: A Review of the Literature |
title_sort | clinical implications of helicobacter pylori antibiotic resistance in italy: a review of the literature |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598780/ https://www.ncbi.nlm.nih.gov/pubmed/36290110 http://dx.doi.org/10.3390/antibiotics11101452 |
work_keys_str_mv | AT nistaenricocelestino clinicalimplicationsofhelicobacterpyloriantibioticresistanceinitalyareviewoftheliterature AT pellegrinoantonio clinicalimplicationsofhelicobacterpyloriantibioticresistanceinitalyareviewoftheliterature AT giulilucia clinicalimplicationsofhelicobacterpyloriantibioticresistanceinitalyareviewoftheliterature AT candellimarcello clinicalimplicationsofhelicobacterpyloriantibioticresistanceinitalyareviewoftheliterature AT schepistommaso clinicalimplicationsofhelicobacterpyloriantibioticresistanceinitalyareviewoftheliterature AT deluciasarasofia clinicalimplicationsofhelicobacterpyloriantibioticresistanceinitalyareviewoftheliterature AT ojettiveronica clinicalimplicationsofhelicobacterpyloriantibioticresistanceinitalyareviewoftheliterature AT franceschifrancesco clinicalimplicationsofhelicobacterpyloriantibioticresistanceinitalyareviewoftheliterature AT gasbarriniantonio clinicalimplicationsofhelicobacterpyloriantibioticresistanceinitalyareviewoftheliterature |